Member Info for Sm66

It appears the RNS has fueled the trolls, posters claiming to be invested and berating this investment. It is a pity the company failed to review the year end estimate and instead posted the negative impact imposed by the government. When they predicted the £100m year end revenue, infection rates where much, much lower. Even at the lowest monthly infection rates we were making £7m per month. The Mcap is too low and PE ratio on LSE at 1.244 is insane for a business with this much revenue and cash at bank. I do agree with some seemingly genuine posters that the BOD now need to step up and show some support by either investing in their company or at the very least publish Q3 results.

Temuchin
They haven’t reported the spin because it won’t be factual until orders actually increase, my understanding is they can only RNS facts, not speculation. Many companies are not included in this list. Nova are, surely this reduces the competition, probably worth noting that the UK, according to the company only produces 1/3 of total revenue. Still grossly undervalued IMHO

Does anyone consider the probability that promote sales will now significantly increase as the supply chain of diagnostics has been reduced by the government?

Investorsteve
Excellent post sir!

Whilst looking at today’s infection rates, it dawned on me that the revenue varied between £10m and £7m per month for the first 6 months of this year.
Looking at infection rates in Q3 there has clearly been a steady increase with numbers substantially higher than Q1 & Q2. One would think that revenue would be higher than the estimated £10m per month on these volumes of infection?

Thanks Larry.

Larry
Where did you get this information?
I didn’t vote on the first round but have voted this time in favour of all solutions.
I figure if I’m invested in the company then I’m invested in the BOD’s.
Really hope the new CEO can put this back on track?

https://www.medrxiv.org/content/10.1101/2021.10.08.21264742v1

I’d just woken up and thought after I posted that it would most likely be corrected, so thankyou.
I was attempting to share positive news after a few post I’ve read over the weekend on institutions downgrading this share.
Personally, I believe that now the company has drawn a line under the SFO investigation (their words) that this can only rise from here?

Citigroup has almost doubled its target price for PFC from 140p to 220p.

Seriously
That would drop the PE ratio below 1. Anything is possible but the company would have enough cash to buy itself from the market. That means any more revenue that’s generated (and it is generating revenue) is meaningless.
Sentiment here is ridiculously low because of poor communication and lack of clarity going beyond COVID and of course the DHSC fiasco.
The new CEO has his work cut out for him, this remains strongly undervalued IMO.

Kitzie
Perfect answer, thank you very much.

Does novacyt have an instrument for measuring antibody levels?
I apologise if it’s in an RNS or has been mentioned before.

Just comparing avacta figures.
Revenue £2.3m, operating loss £11.8m Mcap £281m

Novacyt revenue £100m £77m cash in bank, expanding sales and products, Mcap £198m WTAF?

Investorsteve
I fully agree with your statement.
Which is why I’m holding.
I have to admit, my first purchase here was at 532p but have averaged down to 385p. Now hold a fairly significant amount of shares, therefore I’m glued to this BB when I’m not working.
I remain convinced this share is undervalued.
VGLA

Davand
Thankyou for answering that question.
If that is indeed the case, then today’s RNS is good news regarding revenue.
The company continue to expand their product range and in a timely fashion with winter now clearly upon us. Infection rates have been growing this past month and now solidly in the mid 30,000s every day, would be nice to know our market share.

Good news with new products being launched, not such good news regarding self use LFT’s.
My question is how will today’s news affect revenue. One would imagine that new products would generate new revenue? Was the YE forecast based on the delayed LFT’s. More clarity required IMO.

Mr big
Hahaha funny.
Actually, might be showing my age here but, great tune!

It’s a long way from over Ade.
You might say it’s just beginning.
New CEO in a couple of weeks, his first job should be to resolve the DHSC issue.
Revenue is coming in, cash is in the bank, testing is here for the foreseeable future.
Share price is ridiculously low due to many factors however, this is a company with no debt and a pile of cash. Time will tell but I’m staying in to see what the new CEO is capable of.

IG showing sell 290p, buy 302p. 4% split. Interesting?
Message sent loud and clear to the BOD.
We still know we had a 50% increase in revenue in the first half of 2021, stated cash in bank is pessimistic at best, given the cash they’ve put aside to cover worst case outcome with DHSC.
Soon this company will have more cash than its MCAP?